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SURGERY FOR ACQUIRED 
HEART DISEASE 
THE CARPENTIER-EDWARDS 
PERICARDIAL AORTIC 
VALVE 
Ten-year results 
To evaluate the function of the Carpentier-Edwards pericardial valve in the 
aortic position, we analyzed the results of 310 aortic valve replacements 
performed between 1982 and 1985. Mean age was 64.2 _ 10.8 years (range 22 
to 95 years); 190 patients (61.3%) were male patients. There were 18 hospitai 
deaths (5.8%), and none were valve related. Follow-up of the 292 survivors was 
100% complete at a mean of 7.8 - 2.9 years; 2290 patient-years of follow-up 
were available for analysis. There were 133 late deaths (45.5%). Actuarial 
survivals at 5 and 10 years were 82.5% and 45.9%, respectively. The 10-year 
actuarial freedom fa'om events was 88.7% + 2.1% for thromboembolism, 
90.9% - 1.8% for hemorrhage, 94.3% _+ 1.6% for endocarditis, and 91.2% _ 
2.6% for structural deterioration. The 153 hospital survivors 65 years of age or 
older had an extremely low incidence of structural valve deterioration, with 
only four explants and 95.5% actuarial freedom from explantation at10 years, 
and a linearized rate of 0.3 - 0.2 per patient-year compared with 88.6% and 0.7 
-+ 0.2 for patients younger than 65 years of age. Twelve valves were explanted 
for structural deterioration. Of these, 11 (93%) had leaflet calcification causing 
stenosis and one had a wear-related leaflet tear. The Carpentier-Edwards 
pericardial valve has a low incidence of valve-related complications. The 
freedom from structural valve deterioration is low at 10 years, particularly in 
patients 65 years of age and older. (J THORAC CARDIOVASC SURG 1995;110: 
651-62) 
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T wenty:years of experience with porcine bio- prosthetic valves in the aortic position has 
shown a tow incidence of thromboembol ic  com- 
plications, 1'2 restrictive hemodynamics in small 
sizes, 3-ó and an incidence of structural deteriora- 
tion of 20% at 10 years. 7 This rate of structural 
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valve deterioration is exactly what Carpentier, the 
originator of the glutaraldehyde fixation process, 
had predictedfi This limited durability has been 
the major factor restricting the use of porcine 
valves. In 1971 Ionescu introduced valves con- 
structed of bovine pericardium. 9 This valve and 
other pericardial valves had excellent hemody- 
namics but an unacceptably high rate of structural 
deterioration, which resulted in many interested 
observers condemning pericardium as a material 
for valve construction. 1°-12 
The Carpentier-Edwards pericardial valve (Bax- 
ter Healthcare Corp., Edwards Division, Santa Ana, 
Calif.) introduced in 1980 was the result of major 
design alterations. In vitro testing raised expecta- 
tions for excellent hemodynamics and vastly im- 
proved durability. 13 The hemodynamic advantage of 
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Fig. 1. Actuarial survival for patients discharged from the hospital was 46% at 10 years. Bars represent 1
standard error. 
Tab le  I. Surgical procedure (n = 310) Table II. Late events (n = 100) 
Procedure n % No. 
Isolated AVR 135 43.5 Thromboembolism 36 
AVR and CABG 127 41.0 Endocarditis 19 
AVR and other valve 37 11 .9  Anticoagulant-related h morrhage 24 
AVR and other 11 3.6 Valve explantation 21 
CABG, Coronary artery bypass grafts. 
this valve over porcine valves has been confirmed 
clinically) 4 A few clinical reports with limited fol- 
low-up have shown excellent results and have hinted 
at an excellent freedom from structural valve dete- 
rioration, a5-17 Widespread use is dependent on re- 
ports of  valve durability at 10 years and beyond. 
Pat ients  and  methods  
Between June 1982 and July 1985, 310 patients had 
Carpentier-Edwards pericardial valves (model 2700) in- 
serted in the aortic position. Mean age was 64.2 -- 10.8 
years (range 21 to 95 years); 142 patients (45.8%) were 
less than 65 years of age, and 190 (61.3%) were male; 203 
patients (66%) were in New York Heart Association 
functional class III or IV; 102 patients (33%) were in 
functional class II; 40 patients (12.9%) underwent reop- 
erations. Indications for aortic valve replacement (AVR) 
were aortic stenosis in 93 patients (30%), aortic insufii- 
ciency in 40 (13%), mixed lesions in 154 (50%), and failed 
prosthesis in 23 (7%). Significant coronary artery disease 
was present in 130 patients (41.4%), and 64 patients 
(20.7%) had other coexisting valvular disease. Valve sizes 
implanted were as follows: 19 mm in 64 patients (20.6%), 
21 mm in 99 patients (31.9%), 23 mm in 93 (30.0%), and 
25 mm in 54 (17.4%). The surgical procedures are listed in 
Table I. 
Follow-up information was obtained uring outpatient 
clinic appointments or documented by telephone inter- 
views made between 6 and 12 months during the first 
postoperative y ar and annually thereafter. Follow-up of 
292 hospital survivors was 100% complete at a mean of 
7.8 - 2.9 years with 2290 patient-years of follow-up 
available for analyses. Follow-up of 138 late survivors was 
100% complete at a mean of 9.9 -+ 0.9 years; 1362 
patient-years were available for analysis. 
Patients routinely received waffarin sodium (Coumadin) 
for 12 weeks after the operation. The continuation of 
warfarin beyond this time period, usually for patients in atrial 
fibrillation, was at the discretion of individual cardiologists. 
Ninety percent of patients were discharged receiving antico- 
agulant herapy. At recent foUow-up, 75 of 138 patients 
(54.3%) continued to receive anficoagulation therapy. 
Statistical analyses. The guidelines for reporting mor- 
bidity and mortality after cardiac valvular operations TM 
were used in this report. Death and event-free survival 
estimates were calculated by the method of Kaplan and 
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Fig. 2ù Actuarial freedom from thromboembolism was 89% at 10 years. The hazard function curves 
suggest higher early risk. Bars represent 1 standard error. 
Meier .  19 Cox 's  20 proportional hazards models were used 
to assess the relationship between various factors and 
event-free survival. In all cases, p values less than 0.05 
were cons!dered Significant. Linearized rates for late 
events represent the number of events per 100 patient- 
years. Semi-parametric hazard curves were generated by 
modeling the hazard function as a quadratic function of 
time with the use of a logistic regression model. 
Freedom fi'om structural valve deterioration curves 
were assessed with the use of the method of Grunkemeier 
and associates 21 (Appendix). Rather than using actuarial 
risk, which reflects valve lee as though patients were 
immortal, Grunkemeier's "actual risk" adjusts the curves 
for the fact that many patients will die of other causes 
before structural valve deterioration. According to this 
methodology, patients who die without ever having struc- 
tural valve deterioration are treated as patients who will 
never have structural valve deterioration rather than 
patients who might have had structural valve deterioration 
had they lived. Parametric Weibull models and nonpara- 
metric Kaplan-Meier models were evaluated, and the 
Weibull distribution was determined to fit the data weil. 
Results 
There were 18 hospital  deaths (5.8%). None were 
valve related. There were 133 late deaths (46%), of 
which 91 (68%) were cardiac related. Late deaths 
were cardiac re lated in 91 patients and noncardiac 
654 Cosgrove et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
September 1995 
100 
90 
P" 80 Z 
W 
O n- 
MJ 
D. 70 
60-  
50 
# AT 0 
RISK 292 
0.8 + 0.3 %/pt .  yr. 
I I I I I I I I I 
1 2 3 4 5 6 7 8 9 10 
277 269 258 247 234 216 198 177 132 61 
YEARS 
94% 
20 
15 
A 
a 
lO 
N 
'I" 
0 
0 1 2 3 4 5 6 7 8 9 10 
YEARS 
Fig. 3. Actuarial freedom from endocarditis was 94% at 10 years. The hazard function curves uggest a 
constant risk. Bars represent 1 standard error. 
in 42 patients. Actuarial survival rates at 5 and 10 
years were 82.5% _+ 2.2% and 45.9% _+ 3.2%, 
respectively (Fig. 1). At recent follow-up, 113 pa- 
tients (82%) were in New York Heart Association 
functional class I, 20 patients (15%) were in func- 
tional class II, and five (3%) were in class III or IV. 
In the 292 hospital survivors, there were 100 late 
events (Table II). Ten-year actuarial freedom from 
thromboembolism was 88.7% _+ 2.1% (Fig. 2). 
Thirteen patients had 19 episodes of endocarditis, 
and the actuarial freedom from endocarditis was 
94.3% _ 1.6% at 10 years (Fig. 3). There were 24 
episodes of significant anticoagulation-related h m- 
orrhage resulting in a 10-year actuarial freedom of 
90.9% + 1.8% (Fig. 4). The annualized rate for 
these complications i found in Table III. 
Twenty-one valves were explanted. Three valves 
were removed for endocarditis, and six were re- 
moved prophylactically at the time of mitral valve 
surgery. Twelve valves were explanted for structural 
deterioration. Of these, 11 had leattet calcification, 
and one had a wear-related tear. Mean interval from 
implantation to explantation date for structural de- 
terioration was 8.16 _+ 1.7 years (range 4.5 to 10 
years). Actuarial freedom from explantation for 
structural deterioration at 10 years was 91.2% +_ 
2.7% (Fig. 5). Actual freedom from structural valve 
deterioration was 96% (Fig. 6). Actual freedom 
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Fig. 4. Actuarial freedom from anticoagulant related hemorrhage was91% at l0 years. The hazard 
function curve suggests a higher early risk. Bars represent 1 standard error. 
from structural valve deterioration at 10 years was 
97% for patients 65 years of age or older and 94% 
for patients less than 65 years of age (Fig. 7). 
Although age less than 65 years was a univariately 
significant predictor for explantation for all causes 
(p = 0.0002), it was not found to be a significant 
predictor for explantation caused by structural de- 
terioration (p = 0.452). 
Event-free survival at 5 and 10 years was 69.9% _+ 
2.7% and 37.2% _+ 3.1%, respectively (Fig. 8). 
Multivariate analyses identified age of 65 years or 
older (p = 0.0002) and coronary artery disease (p = 
0.0001) as significant risk factors. 
Table III. Annualized rates 
Thromboembolism 
Hemorrhagic complications (anticoagulant-related 
Endocarditis 
Structural deterioration 
All four events 
1.6 _+ 0.3 
1.0 _+ 0.2 
0.8 _+ 0.3 
0.5 _+ 0.1 
3.9 _+ 0.5 
Values are mean percentage per patient-year _+ standard error. 
The freedom from all events was 85.8% _+ 2.2% 
and 68.5% _+ 3.5% at 5 and 10 years, respectively 
(Fig. 9). Multivariate analysis identified concomitant 
valve surgery as the sole predictor of late events 
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Fig. 5. Actuarial freedom from structural valve deterioration was 91% at 10 years. The hazard function 
curve suggests a slowly rising incidence over time. Bars represent 1 standard error. 
(p < 0.002). The freedom from events was 72% _+ 
4% at 10 years for patients with only aortic valve 
disease and 56% -+ 7% for patients with other valve 
disease, including concomitant coronary artery dis- 
ease (p = 0.002) (Fig. 10). Analyses of patients who 
underwent isolated AVR, AVR and other valve 
procedures, and AVR and coronary artery bypass 
grafting showed an actuarial survival of 53.8% -+ 
4.7% for those undergoing isolated AVR, 38.7% _+ 
5.3% for patients who had an additional valve 
procedure, and 34.7% + 9.2% if concomitant coro- 
nary artery bypass grafting was performed (Fig. 11). 
Actuarial freedom from late events for these three 
groups of patients is 73.7% ___ 4.6%, 68.1% __ 6.7%, 
and 46.2% +_ 9.7%, respectively (Fig. 12). 
Discussion 
The introdu¢tion of valves ¢onstructed ofpericar- 
dium by Ionescu and asso¢iates 9 in 1971 offered an 
alternative to glutaraldehydc-trcated porcine valves. 
Flow studies howcd superior hemodynamic charac- 
teristics,22, 3 and durability testing predi¢ted limited 
durability of the valve and mode of failure) 4' 2s 
These predictions were confirmed in ¢lini¢al experi- 
ence. 1°-12 The Ioncscu-Shiley valve (Shilcy, Inc., 
Irvine, Calif.) had excellent hemodynamics22; how- 
ever, structural detcrioration appeared within 2 to 6 
years.ll, 26-30 Pericardial valves ¢onstructed in a sim- 
ilar fashion produced hemodynamic and durability 
results paralleling those of the Ionescu-Shiley 
valveJl, 31 These results raised doubts in the surgical 
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community as to the appropriateness of glutaralde- 
hyde-treated bovine pericardium for valve construc- 
tion. 
The Carpentier-Edwards pericardial valve re- 
sulted from significant design modifications. 16The 
most important difference between the Carpentier- 
Edwards and other pericardial valves is that the two 
pieces of pericardium of adjacent cusps pass be- 
tween the two arms of the stent rather than over the 
stent. Additionally, it has a flexible stent and the 
shape of the pericardial cusps are the result of finite 
element analysis. The cusps are matched for thick- 
ness and treated with surfactant to retard calcification. 
In vitro hemodynamic data obtained by Gabbay 
and Frater 13 suggested that this valve had excellent 
hemodynamics. These findings were confirmed by 
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clinical evaluations comparing the hemodynamic 
performance of the standard and SupraAnnular 
Carpentier-Edwärds porcine valves with the Car- 
pentier-Edwards pericardial valve. 14 The latter was 
superior in providing adequate hemodynamics-- 
even in the 19 mm size. Pelletier 17 and Frater 16 and 
their associates reported similar findings u ing echo- 
cardiographic data. 
In vitro wear-testing of Carpentier-Edwards peri- 
cardial valves by Gabbay and Frater ~3 raised expec- 
tations for improved urability when compared with 
results from porcine or other valves constructed of
bovine pericardium. Three clinical reports show 
structural deterioration data for thisvalve. Pelletier 
and associates 17 reported a 5-year freedom from 
primary tissue failure of 100% in 181 valves. Perier 
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Fig, 11. The actuarial survivals at 10 years for isolated AVR, AVR and other valve procedures, and AVR 
and coronary artery bypass grafting were 54%, 39%, and 35%, respectively. Bars represent 1 standard error. 
and associates 15found a 100% freedom from struc- 
tural valve deterioration at 9 years in 124 patients. 
Frater and associates 16 reported a freedom from 
structural valve deterioration of 97.2% at 7 years in 
719 patients. Eight of 15 valve replacements were 
for structural valve deterioration as a result of 
stenosis. This report extends the follow-up to 10 
years, and freedom from structural valve deteriora- 
tion remains superb at 94%. It is noteworthy that all 
structural valve deteriorations previously reported 
were a result of calcification. 16We recognized a
leaflet ear in a valve removed from a patient 8 years 
after implantation. This extremely low incidence of 
leaflet tears is unquestionably a result of design 
improvements. 
Recent large series 32-36 (Table IV) evaluating 
porcine valves report widely differing percentages 
for 10-year freedom from structural valve deteriora- 
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Table IV. Porcine valves: lO-year freedom from 
structural valve deterioration 
Freedom from structural 
Principal investigator n valve deterioration 
Jones (1990) 32 522 79% 
Magilligan (1990) 33 492 76% 
Jamieson (1988) 34 572 83% 
Burdon (1992) 35 857 85% 
Akins (1990) 36 429 91% 
tion ranging from 76% to 91%. Three of these 
series32, 33, 35 report on the Hancock porcine valve. 
Ten-year and 15-year freedoms from structural 
valve deterioration were 76% to 86% and 37% to 
63%, respectively. The two remaining series 34'36 
studied Carpentier-Edwards porcine valves and re- 
ported 10-year freedom from structural valve dete- 
rioration of 83% and 91%. The average 10-year 
freedom from structural valve deterioration is 83%. 
Because structural deterioration has been the 
Achilles heel of all previous biologic valves, a signif- 
icant improvement in valve durability has major 
implications for surgeons and patients undertaking 
valve replacement. I  has long been recognized that 
porcine valves do not have the same failure rate in 
all patients. 37' 38 Magilligan and associates 33 were 
the first to point out the high incidence of structural 
valve deterioration i  young patients. Jamieson and 
associates 34 stratified patients according to age, 
pointing out that freedom from structural valve 
deterioration improves with advancing age. They 
further observed that structural valve deterioration 
occurred more frequently in the mitral position. 
Most recently, Jones and associates 32 focused out 
attention on age as a factor in the decision-making 
process, and in subsequent publications 39noted the 
important implications of concomitant coronary ar- 
tery disease affecting the choice of valves. 
These findings prompted Starr and Grunke- 
meier 4° to evaluate the methods of analysis of 
structural valve deterioration. They pointed out that 
actuarial analyses may not be the most appropriate 
method for presenting data on structural valve 
deterioration for clinical decision making. Actu- 
arial studies are designed to evaluate survival 
probabilities. They have also been applied to the 
evaluation of nonfatal events. Actuarial curves 
censor death and thus provide an estimate of the 
probability of structural valve deterioration if all 
patients survived until their valves failed. This 
method is useful in comparing valves, but it is less 
applicable to the decision making when patients 
die. Clearly, actuarial analysis overestimates that 
structural valve deterioration rate, and this error 
is rnagnified with increasing a e. The actual risk of 
a nonfatal event has more clinical relevance be- 
cause it describes percentage of patients with 
structural valve deterioration, given the fact that 
death does intervene. 
In an attempt to guide the patient's and surgeon's 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 110, Number 3 
Cosgrove et al. 6 6 1 
decision regarding the most appropriate valve 
choice, we have adopted the actual risk of structural 
valve deterioration from Grunkemeier and associ- 
ates 21 and compared it with the actuarial risk of 
structural deterioration. The comparison of the two 
makes it apparent hat the actuarial risk of struc- 
tural valve deterioration appears to be higher than 
the actual risk of structural valve deterioration. It is 
apparent that a risk of structural valve deterioration 
in patients 65 years of age and older is extremely 
low. This statistical method seems to be the more 
appropriate way of evaluating biologic valves, par- 
ticularly in older patients. 
The superior hemodynamics and the low inci- 
dence of structural valve deterioration of the Car- 
pentier-Edwards valve have made it our biologic 
valve of choice. Its excellent results in patients 65 
years of age and older has proven its efficacy in this 
age group. These findings have important implica- 
tions for younger patients whose life expectancy is
limited because of concomitant disease. As the 
follow-up stucly achieves 15 years, it may be possible 
to extend present age limitations where the Carpen- 
tier-Edwards pericardial valve is used. 
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Appendix 
The SAS module, PROC LIFEREG (SAS Institute, 
Inc., Cary, N.C.), was used to estimate a time to death 
distribution and a time to failure distribution. Both of the 
distributions were fit from the Weibull family as suggested 
by Grunkemeier. This analysis is achieved in PROC 
LIFEREG by using the "/dist = weibull" option. That 
part of the process does not require extensive knowledge 
of the SAS programming language. The difläculty in 
applying this methodology is in the translation and 
reparametrization f the SAS program output. 
Let Ssu ~. (t) denote the survival function and fsvd (t) 
denote the failure time distribution in the notation used 
by Grunkemeier. The SAS output provides a mean param- 
eter and a scale parameter for each weibull distribution (tL, 
and er). This notation is not the standard notation for a 
Weibull distribution, so new parameters (3' and a) were 
computed as 3' = 1/~ and a = exp{-/x/cr}, with exp{x} 
denoting e x. Now, Ssu~v (t) = exp{-atr}, where a = 
exp{-/Xsu~v/«surv} and 7 = 1/«~u~v. And fsvd = °~'~ t (3 , - l )  
exp{-atv}, where a = exp{--/X~vd/~&v d} and 7 = lk&va. 
The "actual" failure time distribution can now be 
computed with Grunkemeier's formula, J~rt=oS~u~v(t)f~a(t)dt. 
Numeric integration was used to compute this integral for 
each particular value of T. 
